JP2002525099A5 - - Google Patents

Download PDF

Info

Publication number
JP2002525099A5
JP2002525099A5 JP2000572253A JP2000572253A JP2002525099A5 JP 2002525099 A5 JP2002525099 A5 JP 2002525099A5 JP 2000572253 A JP2000572253 A JP 2000572253A JP 2000572253 A JP2000572253 A JP 2000572253A JP 2002525099 A5 JP2002525099 A5 JP 2002525099A5
Authority
JP
Japan
Prior art keywords
polypeptide
seq
variant
native
immune response
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2000572253A
Other languages
English (en)
Japanese (ja)
Other versions
JP2002525099A (ja
JP4243792B2 (ja
Filing date
Publication date
Priority claimed from US09/164,223 external-priority patent/US7063854B1/en
Application filed filed Critical
Priority claimed from PCT/US1999/022819 external-priority patent/WO2000018795A2/en
Publication of JP2002525099A publication Critical patent/JP2002525099A/ja
Publication of JP2002525099A5 publication Critical patent/JP2002525099A5/ja
Application granted granted Critical
Publication of JP4243792B2 publication Critical patent/JP4243792B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

JP2000572253A 1998-09-30 1999-09-30 Wt1特異的免疫療法のための組成物および方法 Expired - Fee Related JP4243792B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US09/164,223 US7063854B1 (en) 1998-09-30 1998-09-30 Composition and methods for WTI specific immunotherapy
US09/164,223 1998-09-30
US27648499A 1999-03-25 1999-03-25
US09/276,484 1999-03-25
PCT/US1999/022819 WO2000018795A2 (en) 1998-09-30 1999-09-30 Compositions and methods for wt1 specific immunotherapy

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2006227215A Division JP2007001984A (ja) 1998-09-30 2006-08-23 Wt1特異的免疫療法のための組成物および方法

Publications (3)

Publication Number Publication Date
JP2002525099A JP2002525099A (ja) 2002-08-13
JP2002525099A5 true JP2002525099A5 (https=) 2005-06-09
JP4243792B2 JP4243792B2 (ja) 2009-03-25

Family

ID=26860363

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2000572253A Expired - Fee Related JP4243792B2 (ja) 1998-09-30 1999-09-30 Wt1特異的免疫療法のための組成物および方法
JP2006227215A Pending JP2007001984A (ja) 1998-09-30 2006-08-23 Wt1特異的免疫療法のための組成物および方法
JP2007279673A Expired - Fee Related JP4235984B2 (ja) 1998-09-30 2007-10-26 Wt1特異的免疫療法のための組成物および方法

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2006227215A Pending JP2007001984A (ja) 1998-09-30 2006-08-23 Wt1特異的免疫療法のための組成物および方法
JP2007279673A Expired - Fee Related JP4235984B2 (ja) 1998-09-30 2007-10-26 Wt1特異的免疫療法のための組成物および方法

Country Status (25)

Country Link
EP (1) EP1117687B1 (https=)
JP (3) JP4243792B2 (https=)
KR (1) KR100752065B1 (https=)
CN (1) CN100486995C (https=)
AR (1) AR021849A1 (https=)
AT (1) ATE399179T1 (https=)
AU (1) AU6407899A (https=)
BR (1) BR9914116A (https=)
CA (1) CA2349442C (https=)
CZ (1) CZ20011144A3 (https=)
DE (1) DE69938970D1 (https=)
ES (1) ES2310052T3 (https=)
HK (1) HK1039782B (https=)
HU (1) HUP0103598A3 (https=)
IL (2) IL142216A0 (https=)
MX (1) MXPA01003344A (https=)
MY (1) MY139226A (https=)
NO (1) NO325839B1 (https=)
NZ (1) NZ510600A (https=)
PL (1) PL201881B1 (https=)
RU (1) RU2237674C2 (https=)
SA (1) SA00200872B1 (https=)
TR (1) TR200101482T2 (https=)
TW (1) TWI285648B (https=)
WO (1) WO2000018795A2 (https=)

Families Citing this family (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2243235C (en) 1996-01-17 2010-08-10 Imperial College Innovations Limited Immunotherapy using cytotoxic t lymphocytes (ctl)
AU4932199A (en) * 1998-07-31 2000-02-21 Haruo Sugiyama Cancer antigens based on tumor suppressor gene wt1 product
US7063854B1 (en) 1998-09-30 2006-06-20 Corixa Corporation Composition and methods for WTI specific immunotherapy
US20030235557A1 (en) * 1998-09-30 2003-12-25 Corixa Corporation Compositions and methods for WT1 specific immunotherapy
US7329410B1 (en) 1998-09-30 2008-02-12 Corixa Corporation Compositions and method for WT1 specific immunotherapy
US7901693B2 (en) 1998-09-30 2011-03-08 Corixa Corporation Compositions and methods for WT1 specific immunotherapy
US20030072767A1 (en) * 1998-09-30 2003-04-17 Alexander Gaiger Compositions and methods for WT1 specific immunotherapy
US7655249B2 (en) 1998-09-30 2010-02-02 Corixa Corporation Compositions and methods for WT1 specific immunotherapy
US7144581B2 (en) 2000-10-09 2006-12-05 Corixa Corporation Compositions and methods for WT1 specific immunotherapy
US7115272B1 (en) 1998-09-30 2006-10-03 Corixa Corporation Compositions and methods for WT1 specific immunotherapy
GB9823897D0 (en) * 1998-11-02 1998-12-30 Imp College Innovations Ltd Immunotherapeutic methods and molecules
WO2001025273A2 (en) * 1999-10-04 2001-04-12 Corixa Corporation Compositions and methods for wt1 specific immunotherapy
CA2401070A1 (en) * 2000-02-22 2001-08-30 Corixa Corporation Compositions and methods for diagnosis and therapy of malignant mesothelioma
JP4592641B2 (ja) * 2000-05-24 2010-12-01 治夫 杉山 Wt1関連疾患の検査方法
JP3846199B2 (ja) 2000-05-24 2006-11-15 治夫 杉山 Wt1関連疾患の検査方法
EP1371664B1 (en) * 2001-03-22 2008-01-09 International Institute of Cancer Immunology, Inc. Wti modified peptide
ATE494905T1 (de) * 2001-06-29 2011-01-15 Chugai Pharmaceutical Co Ltd Krebsimpfstoff mit einem krebs-antigen auf grundlage des produkts aus dem tumorunterdrückungsgen wt1 und einem kationischen liposom
US7553494B2 (en) 2001-08-24 2009-06-30 Corixa Corporation WT1 fusion proteins
US20050002951A1 (en) * 2001-09-28 2005-01-06 Haruo Sugiyama Novel method of inducing antigen-specific t cells
JP5230891B2 (ja) * 2001-09-28 2013-07-10 株式会社癌免疫研究所 抗原特異的t細胞の新規な誘導方法
WO2003106682A1 (ja) * 2002-06-12 2003-12-24 中外製薬株式会社 Hla−a24拘束性癌抗原ペプチド
WO2004024175A1 (ja) * 2002-09-12 2004-03-25 Haruo Sugiyama 癌抗原ペプチド製剤
ES2331305T3 (es) * 2002-09-20 2009-12-29 International Institute Of Cancer Immunology, Inc. Peptidos de wt1 de tipo sustituido.
ES2332590T3 (es) * 2003-01-15 2010-02-09 International Institute Of Cancer Immunology, Inc. Dimero peptidico.
WO2005001117A1 (ja) * 2003-06-27 2005-01-06 Haruo Sugiyama Wt1ワクチン適応患者の選択方法
KR101213015B1 (ko) * 2003-11-05 2012-12-26 인터내셔널 인스티튜트 오브 캔서 이무놀로지 인코퍼레이티드 Wt1 로부터 유도된 hla-dr 결합성 항원 펩티드
PT1731605E (pt) * 2004-03-31 2010-04-14 Int Inst Cancer Immunology Inc Péptidos antigénicos de cancro derivados de wt1
EP1657250A1 (en) * 2004-11-11 2006-05-17 Charité - Universitätsmedizin Berlin HLA-A *01-binding T-cell epitope of WT1
RU2286146C1 (ru) * 2005-04-12 2006-10-27 Ростовский научно-исследовательский онкологический институт МЗ РФ Способ лечения церебральных метастазов генерализованной меланомы кожи
RU2301061C2 (ru) * 2005-04-28 2007-06-20 Ростовский научно-исследовательский онкологический институт МЗ РФ Способ лечения генерализованной меланомы кожи
CA2631292C (en) 2005-11-30 2014-05-06 International Institute Of Cancer Immunology, Inc. Derivatised wt1 cancer antigen peptides and their use
AU2007218649B2 (en) 2006-02-22 2013-01-10 International Institute Of Cancer Immunology, Inc. HLA-A*3303-restricted WT1 peptide and pharmaceutical composition comprising the same
KR101543622B1 (ko) * 2006-10-17 2015-08-11 온코세라피 사이언스 가부시키가이샤 Mphosph1 또는 depdc1 폴리펩티드를 발현하는 암에 대한 펩티드 백신
EP2341142B8 (en) 2006-12-28 2015-01-14 International Institute of Cancer Immunology, Inc. HLA-A*1101-restricted WT1 peptide and pharmaceutical composition comprising same
BRPI0808084A2 (pt) 2007-02-27 2014-07-22 Int Inst Cancer Immunology Inc Método para ativação de células t auxiliadoras e composição para uso no método.
WO2008106551A2 (en) * 2007-02-28 2008-09-04 The Govt. Of The U.S.A. As Represented By The Secretary Of The Dept. Of Health & Human Serv. Brachyury polypeptides and methods for use
KR101773690B1 (ko) 2007-03-05 2017-08-31 인터내셔널 인스티튜트 오브 캔서 이무놀로지 인코퍼레이티드 암 항원 특이적 t 세포의 수용체 유전자 및 그것에 따라 코드되는 펩티드 및 이들의 사용
EP2216041A4 (en) * 2007-11-20 2012-10-24 Nec Corp METHOD OF INDUCING A CYTOTOXIC T-CELL, CYTOTOXIC T-CELL INDUCTOR AND PHARMACEUTICAL COMPOSITION, AND VACCINE WITH THE INDUCTOR
CA2940962C (en) * 2007-12-05 2018-07-24 International Institute Of Cancer Immunology, Inc. Cancer vaccine composition
AR076349A1 (es) 2009-04-23 2011-06-01 Int Inst Cancer Immunology Inc Peptido auxiliar del antigeno del cancer
CN110542754A (zh) * 2009-05-19 2019-12-06 迈阿密大学 用于体外抗原呈递、评估疫苗功效及生物制剂和药物的免疫毒性的组合物、试剂盒和方法
KR20140009168A (ko) 2010-10-05 2014-01-22 인터내셔널 인스티튜트 오브 캔서 이무놀로지 인코퍼레이티드 헬퍼 t 세포의 활성화 방법
MX2013011363A (es) * 2011-04-01 2014-04-25 Sloan Kettering Inst Cancer Anticuerpos para peptidos citosolicos.
CA2839663A1 (en) 2011-06-28 2013-01-03 International Institute Of Cancer Immunology, Inc. Receptor gene for peptide cancer antigen-specific t cell
JP6163486B2 (ja) 2012-07-02 2017-07-12 大日本住友製薬株式会社 癌抗原ペプチド経皮剤
SG10201705028WA (en) 2012-12-17 2017-07-28 Otsuka Pharma Co Ltd Method for activating helper t cell
EP2974734B1 (en) 2013-03-12 2018-10-10 Sumitomo Dainippon Pharma Co., Ltd. Liquid aqueous composition
SG11201507883SA (en) 2013-03-29 2015-10-29 Sumitomo Dainippon Pharma Co Ltd Wt1-antigen peptide conjugate vaccine
WO2014157704A1 (ja) 2013-03-29 2014-10-02 大日本住友製薬株式会社 Erap1によるトリミング機能をきっかけとしたコンジュゲートワクチン
KR20160007579A (ko) 2013-05-13 2016-01-20 인터내셔널 인스티튜트 오브 캔서 이무놀로지 인코퍼레이티드 면역요법의 임상 효과의 예측법
CN106170297A (zh) * 2013-09-20 2016-11-30 纪念斯隆-凯特琳癌症中心 用于wt‑1‑阳性疾病的组合/辅助疗法
JP6005305B2 (ja) 2014-02-26 2016-10-12 テラ株式会社 Wt1抗原性ポリペプチド、及び該ポリペプチドを含む抗腫瘍剤
ES2805094T3 (es) * 2014-12-11 2021-02-10 Int Inst Cancer Immunology Inc Inmunoterapia WT1 para enfermedad angiogénica intraocular
JP6947720B2 (ja) * 2015-09-10 2021-10-13 メモリアル スローン ケタリング キャンサー センター T細胞療法による多発性骨髄腫及び形質細胞白血病の治療方法
SMT202200370T1 (it) * 2015-11-20 2022-11-18 Memorial Sloan Kettering Cancer Center Composizione per il trattamento del cancro
CN105254760B (zh) * 2015-11-21 2018-08-17 福州迈新生物技术开发有限公司 一株分泌抗wt1蛋白的单克隆抗体及其应用
US12383608B2 (en) 2016-11-30 2025-08-12 Sumitomo Pharma Co., Ltd. WT1 helper peptides and combinations of WT1 helper peptide and conjugate of cancer antigen peptides
JPWO2018181648A1 (ja) 2017-03-30 2020-02-13 大日本住友製薬株式会社 Wt1癌抗原ペプチドおよびこれを含むペプチドコンジュゲート体
BR112019020959A2 (pt) * 2017-04-10 2020-05-05 Immatics Biotechnologies Gmbh peptídeos e combinações dos mesmos para uso na imunoterapia contra câncer
MX2020006119A (es) 2017-12-21 2020-08-24 Hoffmann La Roche Anticuerpos de union a hla-a2/wt1.
CN109758575B (zh) * 2018-02-14 2022-08-30 上海微球生物科技有限公司 充分多样的双亲性mhc ii结合多肽、免疫载体微球及其制备方法和应用
JP7162675B2 (ja) 2018-09-28 2022-10-28 住友ファーマ株式会社 注射用組成物
TWI875736B (zh) 2019-02-28 2025-03-11 日商住友製藥股份有限公司 選擇可期待用於治療或預防癌之醫藥組合物之效果之對象之方法
JP7153287B2 (ja) 2020-05-12 2022-10-14 住友ファーマ株式会社 癌を処置するための医薬組成物
WO2021231376A2 (en) * 2020-05-12 2021-11-18 Cue Biopharma, Inc. Multimeric t-cell modulatory polypeptides and methods of use thereof
CN111647066B (zh) * 2020-07-01 2020-12-18 维肽瀛(上海)生物技术有限公司 Wt1多肽肿瘤抑制剂
KR102476515B1 (ko) * 2020-09-11 2022-12-12 한국생명공학연구원 치주 질환 특이 항체 및 이의 용도
KR20220034563A (ko) * 2020-09-11 2022-03-18 한국생명공학연구원 신규 치주 질환 특이 항체 및 이의 용도
MX2024001843A (es) 2021-08-12 2024-05-16 Int Inst Cancer Immunology Inc Composición farmacéutica y método para tratar o prevenir cáncer.
EP4410304A4 (en) * 2021-09-24 2025-08-27 Cha Vaccine Res Institute Co Ltd CANCER VACCINE COMPOSITION COMPRISING PEPTIDES DERIVED FROM A TUMOR-ASSOCIATED ANTIGEN, AND AN ADJUVANT CONSISTING OF A LIPOPEPTIDE AND AN IMMUNOACTIVE SUBSTANCE, AND USE THEREOF

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3393867B2 (ja) * 1989-11-13 2003-04-07 マサチユーセツツ・インステイテユート・オブ・テクノロジー ウィルムス腫瘍遺伝子の位置決定と特徴付け
RU2100369C1 (ru) * 1992-04-22 1997-12-27 Варнер-Ламберт Компани Производные пептида или их фармацевтически приемлемые соли
US5705159A (en) * 1993-08-31 1998-01-06 John Wayne Cancer Institute Immunoreactive peptide sequence from a 43 KD human cancer antigen
US5622835A (en) * 1994-04-28 1997-04-22 The Wistar Institute Of Anatomy & Biology WT1 monoclonal antibodies
WO1999058135A1 (en) * 1998-05-11 1999-11-18 The Salk Institute For Biological Studies Compositions for the treatment of tumors, and uses thereof
AU4932199A (en) * 1998-07-31 2000-02-21 Haruo Sugiyama Cancer antigens based on tumor suppressor gene wt1 product

Similar Documents

Publication Publication Date Title
JP2002525099A5 (https=)
CA2465303A1 (en) Compositions and methods for wt1 specific immunotherapy
US6126945A (en) Tumor killing effects of enterotoxins, superantigens, and related compounds
EP0427347B1 (en) Synthetic peptides useful as universal carriers for the preparation of immunogenic conjugates and their use in the development of synthetic vaccines
JP2008530245A5 (https=)
CA1148146A (en) Cyclopeptides and pharmaceutical preparations thereof and also processes for their manufacture
CA2349442A1 (en) Compositions and methods for wt1 specific immunotherapy
JP2004535187A (ja) アジュバントとしてのコレラホロトキシンの突然変異形
CA2455227A1 (en) Use of biologically active hiv-1 tat, fragments or derivates thereof, to target and/or to activate antigen-presenting cells, and/or to deliver cargo molecules for preventive or therapeutic vaccination and/or to treat other diseases
WO2002028414B1 (en) Compositions and methods for wt1 specific immunotherapy
WO1993024136A1 (en) Tumor killing effects of enterotoxins, superantigens, and related compounds
RU2006105498A (ru) Полипептиды для индукции защитного иммунного ответа против staphylococcus aureus
JP2002531521A5 (https=)
US20170056490A1 (en) Immunogenic composition for use in therapy
DE69828801D1 (de) Peptide abgeleitet vom bindungs (g) protein des respiratorisches synzytialvirus
JP2010514669A5 (https=)
FI924222A0 (fi) Gp75 som ett tumoervaccin mot melanoma.
JP2001515723A (ja) A群連鎖球菌ワクチン
RU2004139053A (ru) Иммуногенные конъюгаты
KR920004422A (ko) Hiv의 주요 중화 결정인자
RU2011120447A (ru) Эпитопные пептиды rab6kifl/kif20a и содержащие их вакцины
JP2020536925A5 (https=)
RU98112608A (ru) Иммуногенная композиция [на основе] tlp
CA2516661A1 (en) M. haemolytica outer membrane protein plpe as a vaccine or vaccine component against shipping fever
EP1785143A2 (en) Vaccine composition against hepatitis c virus